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Nanosized liposomes are among nanotechnological delivery methods for chemotherapeutic 
drugs in the treatment of cancer. This nanotechnology can potentially overcome many 
common pharmacologic problems, such as those involving solubility, in vivo stability, 
pharmacokinetics, tumor uptake and toxicity [1,2]. Liposomes are closed spherical vesicles 
consisting of a lipid bilayer that encapsulates an aqueous phase in which hydrophilic drugs 
can be stored, while water insoluble compounds can be incorporated in the hydrophobic 
region of the lipid bilayer [3]. 
In this work, new synthetic fluorescent antitumoral compounds 1 and 2 [4] were encapsulated 
in nanosized liposomes of DPPC (dipalmitoyl phosphatidylcholine), egg lecithin 
(phosphatidylcholine from egg yolk) and DODAB (dioctadecyldimethylammonium bromide). 
The phospholipids DPPC and egg lecithin (Egg-PC) are neutral components of biological 
membranes, while cationic liposomes based on the synthetic lipid DODAB have been used as 
vehicles for DNA transfection and drug delivery [5]. 
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Methyl 8-(2,3-dimethylbenzo[b]thien-7-yl)-2,3-dimethyl-
6H-thieno[2,3-e]indole-7-carboxylate
           
Monodisperse and nanosized liposomes were prepared by injection of an ethanolic solution of 
the lipid in an aqueous media under vigorous stirring, above the lipid melting transition 
temperature (Tm ~ 41 ºC for DPPC and 45 ºC for DODAB). The hydrodynamic diameters of 
87  11 nm for DPPC, 51  2 nm for Egg-PC and 268  37 nm for DODAB were obtained by 
dynamic light scattering. 
The effect of compounds 1 and 2 on the in vitro growth of three human tumor cell lines, 
breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer 
(SF-268), was evaluated after a continuous exposure of 48h. Values of compound 
concentrations able to inhibit 50% of cell growth (GI50) are shown on Table 1. The 
benzothieno[2,3-b]pyrrole 1 showed the best results, exhibiting lower GI50 values than 
compound 2 in the three tumor cell lines, being significantly more potent against the MCF-7 
and NCI-H460 tumor cell lines. 
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                  Table 1 . Effect of compounds 1 and 2 on the growth of three human  
                   tumor cell lines 
   
Compounds 
 GI50 ( M)  
MCF-7 NCI-H460 SF-268 
1 7.9  0.1 7.9  1.8 14.1  3.0 
2 20.1  16.7
 
16.7  8.6 16.5  9.4
 
                         Results represent means ± SEM of 3-4 independent experiments performed in duplicate.  
                         Doxorubicin was used as positive control, GI50: MCF-7 = 42.8 ± 8.2 nM;  
                       NCI-H460 = 94.0 ± 8.7 nM and SF-268 = 94.0 ± 7.0 nM. 
The intrinsic fluorescence of compounds 1 and 2, due to its high sensitivity and dependence 
on the solvent, was used to obtain information about compounds location in the 
nanoliposomes prepared. Fluorescence emission and anisotropy measurements were 
performed below (gel phase) and above (liquid crystalline phase) the lipid transition 
temperature (figure). The results indicated that compound 1 preferential location is at the lipid 
bilayer, near the polar head groups, while compound 2 prefers generally a more fluid 
environment. These encapsulation experiments are relevant for further studies involving drug 
delivery applications in cancer treatment. 
 
Figure: Normalized fluorescence emission spectra of compounds 1 and 2 incorporated in 
nanoliposomes of DPPC, Egg-PC and DODAB. 
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